Author:
Capelle Martinus A.H.,Babich Lara,van Deventer-Troost J.P. Els,Salerno Doris,Krijgsman Kelly,Dirmeier Ulrike,Raaby Britt,Adriaansen Janik
Subject
Pharmaceutical Science,General Medicine,Biotechnology
Reference41 articles.
1. Centers for Disease Control and Prevention (CDC), 2014 Ebola Outbreak in West Africa – Case Counts. Available at: (last accessed 2 December 2016).
2. The 2014–2015 Ebola saga: lessons for the future;Ayukekbong;J. Epidemiol. Community Health,2016
3. World Health Organisation (WHO), WHO R&D Blueprint: Janssen Vaccines – Jenner Institute complementary Vaccines Platform Technologies 2016. Available at: (last accessed 19 January 2017).
4. Safety and immunogenicity of novel adenovirus type 26– and modified vaccinia ankara-vectored Ebola Vaccines: a randomized clinical trial;Milligan;JAMA,2016
5. O. Anzala, G. Mutua, B.A. Nyaoke, C. Robinson, K. Luhn, B. Callendret, R. Thiebaut, et al., First data in African patients for the Janssen Ebola Zaire heterologous prime-boost vaccine regimen the monovalent Ebola Zaire vaccine, Ad26.ZEBOV/MVA-BN-Filo. International Meeting on Emerging Diseases and Surveillance (IMED) 2016 [abstract].
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献